CO4700441A1 - Nuevo proceso para la produccion de una sal acida calcica amorfa [r-(r*,r*)] -2- (4-fluorofenilo) - , -dihidroxi -5- (1-metiletilo) -3- fenilo -4- [(fenilamino)carbonilo] 1h-pirrol -1- acido heptanoico - Google Patents
Nuevo proceso para la produccion de una sal acida calcica amorfa [r-(r*,r*)] -2- (4-fluorofenilo) - , -dihidroxi -5- (1-metiletilo) -3- fenilo -4- [(fenilamino)carbonilo] 1h-pirrol -1- acido heptanoicoInfo
- Publication number
- CO4700441A1 CO4700441A1 CO96037512A CO96037512A CO4700441A1 CO 4700441 A1 CO4700441 A1 CO 4700441A1 CO 96037512 A CO96037512 A CO 96037512A CO 96037512 A CO96037512 A CO 96037512A CO 4700441 A1 CO4700441 A1 CO 4700441A1
- Authority
- CO
- Colombia
- Prior art keywords
- solvent
- amorphous
- calcica
- dihidroxi
- pirrol
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- -1 1-METHYLETHYL Chemical class 0.000 title 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 title 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000002904 solvent Substances 0.000 abstract 8
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 6
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 6
- 229960005370 atorvastatin Drugs 0.000 abstract 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 3
- 238000001291 vacuum drying Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US145395P | 1995-07-17 | 1995-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4700441A1 true CO4700441A1 (es) | 1998-12-29 |
Family
ID=21696097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO96037512A CO4700441A1 (es) | 1995-07-17 | 1996-07-17 | Nuevo proceso para la produccion de una sal acida calcica amorfa [r-(r*,r*)] -2- (4-fluorofenilo) - , -dihidroxi -5- (1-metiletilo) -3- fenilo -4- [(fenilamino)carbonilo] 1h-pirrol -1- acido heptanoico |
Country Status (37)
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| IN191236B (enExample) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| US6646133B1 (en) | 2000-10-17 | 2003-11-11 | Egis Gyogyszergyar Rt. | Process for the preparation of amorphous atorvastatin calcium |
| HU226640B1 (en) * | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| IL155890A0 (en) * | 2000-11-16 | 2003-12-23 | Teva Pharma | HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| ES2319870T3 (es) | 2000-12-27 | 2009-05-14 | Teva Pharmaceutical Industries Limited | Formas cristalinas de atorvastatina. |
| WO2002057228A1 (en) * | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| IN190564B (enExample) * | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| HUP0400381A2 (hu) | 2001-06-29 | 2004-09-28 | Warner-Lambert Company Llc | [R-(R*,R*)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái |
| US7361772B2 (en) | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
| AU2001284385A1 (en) | 2001-08-31 | 2003-03-10 | Morepen Laboratories Ltd. | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) |
| UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| CZ296967B6 (cs) | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
| RU2309141C2 (ru) * | 2002-03-18 | 2007-10-27 | Байокон Лимитид | АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| JP4308021B2 (ja) | 2002-03-18 | 2009-08-05 | バイオコン・リミテッド | 望ましい粒子サイズのアモルファスＨＭＧ−ＣｏＡレダクターゼ阻害剤 |
| ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
| AU2002356423A1 (en) * | 2002-05-28 | 2003-12-12 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
| AU2002330735A1 (en) * | 2002-09-03 | 2004-03-29 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
| EA013500B1 (ru) * | 2003-04-11 | 2010-06-30 | Лек Фармасьютиклз Д.Д. | Способ получения аморфной кальциевой соли аторвастатина |
| US7232920B2 (en) | 2003-04-22 | 2007-06-19 | Biocon | Process for stereoselective reduction of β-ketoesters |
| US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| AU2003272080A1 (en) | 2003-09-18 | 2005-04-06 | Biocon Limited | Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
| CA2456430A1 (en) * | 2004-01-28 | 2005-07-28 | Brantford Chemicals Inc. | Improved process for the preparation of amorphous atorvastatin calcium |
| CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace |
| CA2666359A1 (en) | 2004-03-17 | 2005-10-06 | Yatendra Kumar | Process for the production of atorvastatin calcium in amorphous form |
| US7875731B2 (en) | 2004-05-05 | 2011-01-25 | Pfizer Inc. | Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid |
| AU2005263550C1 (en) * | 2004-07-16 | 2013-01-17 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
| WO2006021969A1 (en) | 2004-08-27 | 2006-03-02 | Biocon Limited | Process for atorvastatin calcium amorphous |
| KR20070106680A (ko) * | 2004-09-30 | 2007-11-05 | 닥터 레디스 레보러터리즈 리미티드 | 비정질 아토르바스타틴 칼슘 |
| CA2582087A1 (en) * | 2004-10-18 | 2006-04-27 | Teva Pharmaceutical Industries Ltd. | Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent |
| EP1807055A1 (en) * | 2004-10-28 | 2007-07-18 | Warner-Lambert Company LLC | Process for forming amorphous atorvastatin |
| AU2005305460B2 (en) | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| JP2008521878A (ja) * | 2004-12-02 | 2008-06-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 非晶質アトルバスタチンの医薬組成物及びその製造のための方法 |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| JP2007231018A (ja) * | 2006-03-01 | 2007-09-13 | Teva Pharmaceutical Industries Ltd | アトルバスタチンヘミカルシウムの結晶形の調製方法 |
| US20100113802A1 (en) * | 2006-11-02 | 2010-05-06 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate |
| US7834195B2 (en) | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
| EP2185527A2 (en) * | 2007-07-11 | 2010-05-19 | Actavis Group PTC EHF | Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium |
| US20090124817A1 (en) * | 2007-11-09 | 2009-05-14 | The Industry & Academic Cooperation In Chungnam National University | Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles |
| EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
| WO2010066846A2 (en) * | 2008-12-11 | 2010-06-17 | Dsm Ip Assets B.V. | Method for the isolation of atorvastatin |
| EP2327682A1 (en) | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| SI2373609T1 (sl) | 2008-12-19 | 2013-12-31 | Krka, D.D., Novo Mesto | Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| SI1148049T1 (en) | 1995-07-17 | 2005-02-28 | Warner-Lambert Company | Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
-
1996
- 1996-07-03 HR HR960312A patent/HRP960312B1/xx not_active IP Right Cessation
- 1996-07-16 AT AT96924553T patent/ATE199542T1/de not_active IP Right Cessation
- 1996-07-16 DE DE69611999T patent/DE69611999T2/de not_active Revoked
- 1996-07-16 CN CN96195631A patent/CN1087289C/zh not_active Expired - Lifetime
- 1996-07-16 CZ CZ1998122A patent/CZ289421B6/cs not_active IP Right Cessation
- 1996-07-16 EA EA199800128A patent/EA000625B1/ru not_active IP Right Cessation
- 1996-07-16 IL IL12216196A patent/IL122161A/xx not_active IP Right Cessation
- 1996-07-16 AR ARP960103599A patent/AR002849A1/es not_active Application Discontinuation
- 1996-07-16 PT PT96924553T patent/PT839132E/pt unknown
- 1996-07-16 CA CA002220455A patent/CA2220455C/en not_active Expired - Lifetime
- 1996-07-16 SI SI9630284T patent/SI0839132T1/xx unknown
- 1996-07-16 PL PL324463A patent/PL191017B1/pl unknown
- 1996-07-16 WO PCT/US1996/011807 patent/WO1997003960A1/en not_active Ceased
- 1996-07-16 SK SK58-98A patent/SK283204B6/sk not_active IP Right Cessation
- 1996-07-16 NZ NZ313008A patent/NZ313008A/xx not_active IP Right Cessation
- 1996-07-16 MX MX9708959A patent/MX9708959A/es unknown
- 1996-07-16 GE GEAP19964149A patent/GEP20002027B/en unknown
- 1996-07-16 BR BR9609714A patent/BR9609714A/pt not_active Application Discontinuation
- 1996-07-16 JP JP50681497A patent/JP4064459B2/ja not_active Expired - Lifetime
- 1996-07-16 KR KR10-1998-0700348A patent/KR100400805B1/ko not_active Expired - Lifetime
- 1996-07-16 RO RO98-00060A patent/RO120069B1/ro unknown
- 1996-07-16 UA UA98020823A patent/UA50743C2/uk unknown
- 1996-07-16 IN IN1579DE1996 patent/IN185276B/en unknown
- 1996-07-16 AU AU64978/96A patent/AU700794B2/en not_active Expired
- 1996-07-16 EE EE9700369A patent/EE03605B1/xx unknown
- 1996-07-16 EP EP96924553A patent/EP0839132B1/en not_active Revoked
- 1996-07-16 HU HU9903017A patent/HU220343B/hu unknown
- 1996-07-16 ES ES96924553T patent/ES2156997T3/es not_active Expired - Lifetime
- 1996-07-16 DK DK96924553T patent/DK0839132T5/da active
- 1996-07-17 UY UY24286A patent/UY24286A1/es not_active IP Right Cessation
- 1996-07-17 CO CO96037512A patent/CO4700441A1/es unknown
- 1996-07-17 ZA ZA9606043A patent/ZA966043B/xx unknown
- 1996-07-17 PE PE1996000541A patent/PE1698A1/es not_active IP Right Cessation
-
1998
- 1998-01-14 BG BG102188A patent/BG63631B1/bg unknown
- 1998-01-16 NO NO980209A patent/NO309322B1/no unknown
-
2000
- 2000-09-07 US US09/657,469 patent/US6274740B1/en not_active Expired - Lifetime
-
2001
- 2001-05-15 GR GR20010400710T patent/GR3035859T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4700441A1 (es) | Nuevo proceso para la produccion de una sal acida calcica amorfa [r-(r*,r*)] -2- (4-fluorofenilo) - , -dihidroxi -5- (1-metiletilo) -3- fenilo -4- [(fenilamino)carbonilo] 1h-pirrol -1- acido heptanoico | |
| EE05328B1 (et) | Meetod amorfse atorvastatiini valmistamiseks | |
| UY24285A1 (es) | Procedimiento para la preparación de ácido cristalino | |
| DE60106178D1 (de) | Verfahren zur Isolierung von hochgereinigten ungesättigten Fettsäuren mittels Kristallisation | |
| US7563911B2 (en) | Process for the preparation of amorphous atorvastin calcium salt (2:1) | |
| DK0472501T3 (da) | Codeinsalt af en substitueret carboxylsyre, fremgangsmåde til dets fremstilling, dets anvendelse samt farmaceutiske præparater | |
| DE50015006D1 (de) | Verfahren zur katalytischen Vinylierung von Carbonsäuren | |
| AU2001284904A1 (en) | Process for drying organoborane compounds | |
| RU95109936A (ru) | Новые замещенные азетидиноны, способ их получения, фармацевтическая композиция, способ лечения | |
| NO20022619D0 (no) | Fremgangsmåte ved formulding | |
| Schettini et al. | Catalytic Alkylation of 2-Aryl-2-oxazoline-4-carboxylic Acid Esters Using Cyclopeptoids; Newly Designed Phase-Transfer Catalysts | |
| RU97105437A (ru) | Способ получения биологически активной суммы тритерпеновых кислот | |
| ES2137137B1 (es) | Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica. | |
| DK1254110T3 (da) | Proces til fremstilling af 2-hydroxy-4-methylthiosmörsyreestere | |
| DE60024821T2 (de) | Neues Verfahren zur Reinigung von Aldehyd-Verunreinigungen | |
| CA2479005A1 (en) | Amorphous atorvastatin calcium or pravastatin sodium hmg-coa reductase inhibitors of desired particle size | |
| ATE222499T1 (de) | Pharmazeutische zusammensetzung enthaltend einen embryonalen extrakt und verfahren zu ihrer herstellung | |
| ECSP961822A (es) | NUEVO PROCESO PARA LA PRODUCCION DE UNA SAL ACIDA CALCICA AMORFA [R- (R*, R*)]-2-(4- FLUOROFENILO)-ß, 6- DIHIDROXI- 5 - (1- METILETILO)- 3 - FENILO -4-[(FENILAMINO) CARBONILO] - 1H- PIRROL - 1 - ACIDO HEPTANOICO | |
| CA2379821A1 (en) | Mixture for the treatment of waste materials | |
| RU99104297A (ru) | Способ получения производных 3-пирролин-2-карбоновой кислоты | |
| JP3868210B2 (ja) | Ｎ−アシル−３，４−デヒドロプロリンおよびｎ−アシル−３，４−デヒドロピペリジン−２−カルボン酸誘導体の製法 | |
| ES2195925T3 (es) | Proceso para fabricar una formulacion de liberacion retardada. | |
| WO2002068391A8 (en) | Process for resolving racemic mixtures of piperidine derivatives | |
| DE602005013382D1 (de) | Feste formen des magnesiumsalzes von (s)-omeprazol und verfahren zu deren herstellung | |
| DE60004432D1 (de) | Verfahren zur Herstellung von Hydroxamsäuren |